Literature DB >> 25615551

Development and Validation of a Quality-of-Life Instrument for Infantile Hemangiomas.

Sarah L Chamlin1, Anthony J Mancini1, Jin-Shei Lai2, Jennifer L Beaumont2, David Cella2, Denise Adams3, Beth Drolet4, Eulalia Baselga5, Ilona J Frieden6, Maria Garzon7, Kristin Holland4, Kimberly A Horii8, Anne W Lucky9, Catherine McCuaig10, Denise Metry11, Kimberly D Morel7, Brandon D Newell8, Amy J Nopper8, Julie Powell10, Dawn Siegel4, Anita N Haggstrom12.   

Abstract

Infantile hemangiomas (IH) are common tumors for which there is no validated disease-specific instrument to measure the quality of life in infants and their parents/caregivers during the critical first months of life. This study prospectively developed and validated a quality-of-life instrument for patients with IH and their parents/caregivers and correlated demographic and clinical features to the effects on the quality of life. A total of 220 parents/caregivers completed the 35-item Infantile Hemangioma Quality-of-Life (IH-QoL) instrument and provided demographic information. The dimensionality of the items was evaluated using factor analysis, with results suggesting four factors: child physical symptoms, child social interactions, parent emotional functioning, and parent psychosocial functioning. Each factor fit the Rasch measurement model with acceptable fit index (mean square <1.4) and demonstrated excellent internal consistency, with alpha ranging from 0.76 to 0.88. The final instrument consists of four scales with a total of 29 items. Content validity was verified by analyzing parents' responses to an open-ended question. Test-retest reliability at a 48-hour interval was supported by a total IH-QoL intraclass correlation coefficient of 0.84. Certain clinical characteristics of hemangioma, including those located on the head and neck, in the proliferative stage, and requiring treatment, are associated with a greater impact on QoL.

Entities:  

Mesh:

Year:  2015        PMID: 25615551     DOI: 10.1038/jid.2015.18

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

Review 1.  Critical review of generic and dermatology-specific health-related quality of life instruments.

Authors:  Hilde Both; Marie-Louise Essink-Bot; Jan Busschbach; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2007-11-08       Impact factor: 8.551

2.  Infantile haemangiomas and quality of life.

Authors:  Eran Cohen-Barak; Dganit Rozenman; Ayelet Shani Adir
Journal:  Arch Dis Child       Date:  2013-07-17       Impact factor: 3.791

Review 3.  The psychosocial impact of an infantile haemangioma on children and their parents.

Authors:  Jeffrey Zweegers; Carine J M van der Vleuten
Journal:  Arch Dis Child       Date:  2012-08-04       Impact factor: 3.791

4.  Growing up with a facial hemangioma: parent and child coping and adaptation.

Authors:  J L Tanner; M P Dechert; I J Frieden
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

5.  Early growth of infantile hemangiomas: what parents' photographs tell us.

Authors:  Megha M Tollefson; Ilona J Frieden
Journal:  Pediatrics       Date:  2012-07-23       Impact factor: 7.124

6.  Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.

Authors:  Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Brandon Newell; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

Review 7.  Psychosocial development of children with hemangiomas: home, school, health care collaboration.

Authors:  C A Dieterich-Miller; P L Safford
Journal:  Child Health Care       Date:  1992

8.  Growth characteristics of infantile hemangiomas: implications for management.

Authors:  Linda C Chang; Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

9.  Health-related quality of life and impact of haemangiomas on children and their parents.

Authors:  Marije J Hoornweg; Martha A Grootenhuis; Chantal M A M van der Horst
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-07-03       Impact factor: 2.740

10.  Parental experiences with propranolol versus oral corticosteroids for complicated infantile hemangioma, a retrospective questionnaire study.

Authors:  Denise Josephina Johanna Hermans; Jeffrey Zweegers; Andrea Walburga Maria Evers; Catharina Joanna Maria Van Der Vleuten
Journal:  Eur J Dermatol       Date:  2013 Nov-Dec       Impact factor: 3.328

View more
  4 in total

1.  Quality of life in children with infantile hemangioma: a case control study.

Authors:  Chuan Wang; Yanan Li; Bo Xiang; Fei Xiong; Kai Li; Kaiying Yang; Siyuan Chen; Yi Ji
Journal:  Health Qual Life Outcomes       Date:  2017-11-16       Impact factor: 3.186

2.  Improving the patient-centred care of children with life-altering skin conditions using feedback from electronic patient-reported outcome measures: protocol for a hybrid effectiveness-implementation study (PEDS-ePROM).

Authors:  Zephanie Tyack; Megan Simons; Steven M McPhail; Gillian Harvey; Tania Zappala; Robert S Ware; Roy M Kimble
Journal:  BMJ Open       Date:  2021-04-09       Impact factor: 2.692

3.  Development and validation of psychological status questionnaire for parents of infantile hemangiomas.

Authors:  Wei Peng; Haijin Liu; Jincai Chen; Yanan Zheng; Xianyun Xu; Hong Tang; Qian Liu
Journal:  Transl Pediatr       Date:  2021-12

4.  Quality of life improving after propranolol treatment in patients with Infantile Hemangiomas.

Authors:  Marco Pensabene; Maria Rita Di Pace; Fabio Baldanza; Francesco Grasso; Maria Patti; Maria Sergio; Simona La Placa; Mario Giuffre'; Gregorio Serra; Alessandra Casuccio; Marcello Cimador
Journal:  Ital J Pediatr       Date:  2022-08-04       Impact factor: 3.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.